Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call
Prenetics (NASDAQ: PRE) will release its Q4 and full year 2025 financial results for the period ended December 31, 2025 before market open on Wednesday, February 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prenetics (NASDAQ: PRE) will release its Q4 and full year 2025 financial results for the period ended December 31, 2025 before market open on Wednesday, February 18, 2026.
The company will host an earnings conference call the same day at 10:00 a.m. Eastern Time with a Q&A session; an audio replay will be available on the investor relations website.
Details
News Market Reaction – PRE
On Feb 11, the day this news came out, PRE closed 0.14% below the previous close.
Data tracked by StockTitan Argus for the Feb 11 session.
Key Figures
- Earnings date
- February 18, 2026
- Q4 and full-year 2025 results release before market open
- Conference call time
- 10:00 a.m. Eastern Time
- Earnings conference call on February 18, 2026
- Dial-in (US)
- 1-877-425-9470
- Domestic participant access number for earnings call
- Dial-in (Intl)
- 1-201-389-0878
- International participant access number for earnings call
Historical Context
-
Sale of Europa business and focus on IM8 with strong liquidity metrics.
-
High warrant exchange participation reducing potential dilution from October 2025 financing.
-
Cessation of Bitcoin purchases and refocus of capital on IM8 brand growth.
-
Voluntary warrant exchange to simplify capital structure and cut dilution risk.
-
Announcement of December investor conference appearances and related presentations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
| Date: | Wednesday, February 18, 2026 |
| Time: | 10:00 a.m. Eastern Time |
| Dial-in: | 1-877-425-9470 |
| International Dial-in: | 1-201-389-0878 |
| Webcast | PRE Conference Call |
An audio replay of the webcast will be available on the Company’s investor relations website at https://ir.prenetics.com/.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.